National Bank of Canada

National Bank of Canada’s Q32 Bio QTTB Stock Holding History

National Bank of Canada’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	-$8.25K	–	3255
2025 Q1	$8.25K	Buy	+50	New	+$135	﹤0.01%	2285

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

National Bank of Canada's QTTB Position: Q3 2025 in Review

National Bank of Canada sold out of Q32 Bio (QTTB) in Q3 2025, closing a stake of 1 share — an estimated $1 sold.

National Bank of Canada first reported a position in QTTB in Q3 2024 and held it in 4 quarters. The position peaked at $8.31K in Q1 2025. 53 funds tracked by Wall St. Rank hold QTTB as of Q3 2025.

National Bank of Canada reported no remaining Q32 Bio position as of Q3 2025 after selling out during the quarter.
National Bank of Canada sold 1 Q32 Bio share in Q3 2025, an estimated $1.
National Bank of Canada first reported a position in Q32 Bio in Q3 2024 and held it in 4 quarters.
National Bank of Canada's Q32 Bio position peaked at $8.31K in Q1 2025.
53 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.